LC16m8 pre-exposure prophylaxis showed no mpox cases in a randomized controlled trial of high-risk adults
Mpox Vaccine Shows Promise for High-Risk Groups, But Key Questions Remain
This randomized controlled trial enrolled 570 participants in an early-vaccination group and 565 in a late-vaccination group. No mpox cases …
A new mpox vaccine produced strong immune responses in high-risk individuals, including those with HIV, but researchers still can't say for …
Technical report validates AI tool for classifying MPXV subclades using genomic data
New AI tool quickly identifies dangerous mpox virus types from DNA samples
This technical report describes a methodological development for a software tool called CladePredictor-MPXV.
This new AI tool sorts mpox virus types in seconds and helps doctors track dangerous outbreaks faster than ever before
EBOV-specific gene signature identified in nonhuman primates and human cohorts with Ebola infection
New gene signature can spot Ebola infection in blood samples
This observational cohort study analyzed RNA-Seq data from nonhuman primates and human cohorts with Ebola virus infection and comparator inf…
Researchers found a 50-gene signature that reliably separates Ebola from other infections in blood tests, pointing to a future diagnostic to…
Review of genomic surveillance finds concurrent Mpox subclade circulation across Africa
Mpox Is Spreading in Ways Scientists Didn't See Coming
This review synthesizes genomic surveillance data from 24 African Union Member States, covering 3,450 high-quality MPXV virus whole genomes.
Mpox is spreading across Africa in surprising ways, with different strains jumping from animals to people or spreading quietly between human…
Interim clinical treatment considerations for severe mpox manifestations in the United States
U.S. health officials review treatment options for severe mpox cases
A non-peer-reviewed report describes interim clinical treatment considerations for severe mpox manifestations in the United States.
U.S. health officials are reviewing possible treatment approaches for severe mpox cases while more research is needed.
US report describes racial disparities in mpox incidence among adult males
Report describes racial disparities in mpox cases among adult males in the US
An observational report from the United States describes racial and ethnic disparities in mpox incidence among adult males.
A new report shows non-Hispanic Black and Hispanic or Latino males in the US had different mpox infection rates compared to non-Hispanic whi…
Field report describes posttreatment lesions after tecovirimat therapy for mpox in New York City
What happens after mpox treatment? Doctors describe lingering skin lesions
A field report from New York City describes posttreatment lesions in mpox patients who received tecovirimat.
Doctors in New York City report that some mpox patients developed new skin lesions after finishing antiviral treatment.
Report describes shortfalls in mpox vaccination coverage among eligible persons in the US
Report describes shortfalls in mpox vaccination coverage among eligible people in the US
A report describes shortfalls in mpox vaccination coverage among vaccine-eligible persons in the United States.
A new report shows that many people in the United States who are eligible for the mpox vaccine have not yet received it.
Survey explores possible undetected mpox infection among people experiencing homelessness in San Francisco
Did mpox spread undetected among people experiencing homelessness?
A survey was conducted among people accessing homeless services or staying in encampments in San Francisco to explore possible undetected mp…
Health officials surveyed people experiencing homelessness to check for undetected mpox infections that might have spread in hard-to-see pla…
Observational analysis examines mpox cases in New York City
New York City health officials analyze mpox case data to track the outbreak
An observational analysis examined mpox cases in New York City.
New York City health officials analyzed mpox case data from the 2022 outbreak to better understand how the virus was spreading in the city.
Observational report describes mpox features in US adults aged 50+ versus younger adults
Health officials describe mpox features in older adults compared to younger adults
An observational report describes epidemiologic and clinical features of mpox in US adults aged 50 years and older compared to other adults,…
Health officials describe how mpox features in adults over 50 differ from younger adults and how JYNNEOS vaccination status compares.
JYNNEOS vaccine recipients characterized at Louisiana LGBTQIA+ festival
Who got the monkeypox vaccine at a major LGBTQIA+ festival in Louisiana?
A report described characteristics of JYNNEOS vaccine recipients before and during a large multiday LGBTQIA+ festival in Louisiana.
A large monkeypox vaccination event took place at an LGBTQIA+ festival in Louisiana, offering a snapshot of who received the JYNNEOS vaccine…
All Mpox Articles
- LC16m8 pre-exposure prophylaxis showed no mpox cases in a randomized controlled trial of high-risk adults
- Technical report validates AI tool for classifying MPXV subclades using genomic data
- EBOV-specific gene signature identified in nonhuman primates and human cohorts with Ebola infection
- Review of genomic surveillance finds concurrent Mpox subclade circulation across Africa
- Observational analysis examines mpox cases in New York City
- Survey explores possible undetected mpox infection among people experiencing homelessness in San Francisco
- Interim clinical treatment considerations for severe mpox manifestations in the United States
- Observational report describes mpox features in US adults aged 50+ versus younger adults
- Mpox outbreak reported in Los Angeles County, California during summer 2023
- JYNNEOS vaccine recipients characterized at Louisiana LGBTQIA+ festival
- Surveillance report supports safety of JYNNEOS vaccine for mpox prevention
- Possible mpox exposures described in patients without reported male-to-male sexual contact
- US report describes racial disparities in mpox incidence among adult males
- Field report describes posttreatment lesions after tecovirimat therapy for mpox in New York City
- CDC adapted smallpox preparedness and HIV programs for US mpox response
- JYNNEOS vaccine effectiveness against mpox infection studied in New York City surveillance
- Report describes shortfalls in mpox vaccination coverage among eligible persons in the US
- Mpox cluster emerges among previously vaccinated individuals in Chicago investigation
- Mpox cases in US children linked to household contacts or caregivers in descriptive report
- Case series finds no adverse reaction to tecovirimat in four pregnant persons with mpox
- Tecovirimat distribution reported during Los Angeles County mpox outbreak
- Clade Ib mpox cases diagnosed in Kenya from July 2024 to February 2025
- Phase 2 trial assesses JYNNEOS vaccine in adolescents for monkeypox prevention
- ACIP Recommends JYNNEOS Vaccine for Adults at Risk During Mpox Outbreaks
- Paediatric mpox PCR positivity rates range from 6.95% to 35.6% in global systematic review